Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Size (2024 – 2030)

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market was valued at USD 2.7 billion in 2023 and is projected to reach a market size of USD 4.94 billion by the end of 2030. The market is anticipated to expand at a compound annual growth rate (CAGR) of 9% between 2024 and 2030.

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market is witnessing significant growth due to the escalating prevalence of opioid addiction and the urgent need for effective treatment solutions. Buprenorphine, a partial opioid agonist, has emerged as a cornerstone in the management of OUD, offering a safer alternative to full opioid agonists by reducing cravings and withdrawal symptoms without producing the same high. This medication is increasingly favored in clinical practice for its efficacy in facilitating long-term recovery and its relatively low risk of abuse and overdose. The market's expansion is further propelled by rising awareness of OUD as a chronic medical condition, the integration of medication-assisted treatment (MAT) into mainstream healthcare, and supportive government policies and funding. Technological advancements in drug formulation and delivery systems also contribute to the market's growth, enhancing patient compliance and outcomes. Despite these positive trends, challenges such as stigma associated with addiction treatment, regulatory hurdles, and the need for comprehensive care models remain. Nevertheless, with ongoing research and development, the Global Buprenorphine-based OUD Treatment Market is poised for continued advancement, playing a crucial role in addressing the opioid crisis and improving public health outcomes worldwide.

Key Market Insights:

The buprenorphine-based OUD treatment market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2030.

Buprenorphine accounts for approximately 40% of the medication-assisted treatment (MAT) market for opioid use disorders.

Around 60% of patients receiving medication-assisted treatment for OUD in the United States use buprenorphine.

Buprenorphine prescriptions have increased by over 20% annually in recent years, reflecting growing acceptance and utilization.

About 70% of primary care physicians in high OUD prevalence areas are now licensed to prescribe buprenorphine, up from 50% five years ago.

Government funding for buprenorphine-based OUD treatment programs has increased by 25% in the last three years, supporting wider accessibility and adoption.

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Drivers:

Increasing Prevalence of Opioid Use Disorders

The rising prevalence of opioid use disorders (OUD) globally is a significant driver for the buprenorphine-based OUD treatment market. The opioid crisis, marked by a dramatic increase in opioid addiction and overdose deaths, has become a critical public health issue. According to the World Health Organization (WHO), approximately 27 million people globally suffer from opioid use disorders. This alarming statistic underscores the urgent need for effective treatment options, pushing healthcare systems and governments to prioritize addressing this crisis. Buprenorphine, a partial opioid agonist, is increasingly recognized for its effectiveness in reducing cravings and withdrawal symptoms, facilitating long-term recovery, and lowering the risk of abuse compared to full opioid agonists. The growing awareness and acceptance of medication-assisted treatment (MAT) as an essential component of OUD management have significantly boosted the demand for buprenorphine. Additionally, the integration of OUD treatment into primary healthcare settings and the expansion of telemedicine services have further enhanced accessibility to buprenorphine-based therapies, making it easier for patients to receive the care they need. As the opioid crisis continues to escalate, the demand for buprenorphine-based treatments is expected to rise, driving market growth.

Supportive Government Policies and Funding

Supportive government policies and increased funding are pivotal drivers of the buprenorphine-based OUD treatment market. Recognizing the severity of the opioid crisis, governments worldwide have implemented various measures to combat opioid addiction and improve treatment access. In the United States, for example, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act was enacted to enhance the response to the opioid epidemic, including expanding access to medication-assisted treatment (MAT). Such policies encourage the use of buprenorphine as a critical component of OUD treatment, promoting its integration into mainstream healthcare. Additionally, substantial government funding has been allocated to support OUD treatment programs, research, and healthcare provider training. In recent years, funding for buprenorphine-based treatment programs has increased by 25%, reflecting a commitment to addressing the opioid crisis. This financial support helps reduce barriers to treatment, making buprenorphine more accessible to patients. Furthermore, initiatives aimed at reducing the stigma associated with addiction treatment and increasing public awareness about the benefits of MAT contribute to higher acceptance and utilization of buprenorphine. Collectively, these supportive government actions and funding efforts are driving the growth of the buprenorphine-based OUD treatment market.

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Restraints and Challenges:

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market faces several restraints and challenges that hinder its growth. One of the primary challenges is the stigma associated with opioid addiction and its treatment. Many individuals suffering from OUD are reluctant to seek help due to societal judgment and misconceptions about addiction treatment, including medication-assisted treatment (MAT). Additionally, regulatory hurdles and stringent prescribing guidelines can limit the availability and accessibility of buprenorphine. Healthcare providers must undergo specific training and obtain waivers to prescribe buprenorphine, which can deter some from offering this treatment. Another significant challenge is the fluctuating cost of buprenorphine and related therapies, which can be a barrier for patients, particularly those without insurance or with limited financial resources. Furthermore, there is a persistent issue of diversion and misuse of buprenorphine, necessitating stringent monitoring and risk mitigation strategies. The market also faces competition from other MAT options, such as methadone and naltrexone, which may be preferred in certain clinical scenarios. Lastly, while there has been progress in integrating OUD treatment into primary care and telemedicine, disparities in healthcare access, particularly in rural and underserved areas, remain a significant obstacle. Addressing these challenges is crucial for the continued growth and efficacy of the buprenorphine-based OUD treatment market.

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Opportunities:

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market presents numerous opportunities driven by advancements in healthcare delivery and growing recognition of the need for effective OUD treatments. One significant opportunity lies in the expansion of telemedicine services, which can improve access to buprenorphine-based treatments, especially in rural and underserved areas where traditional healthcare facilities are scarce. Telemedicine enables remote consultations and prescriptions, making it easier for patients to initiate and continue treatment. Additionally, increased funding for research and development is opening doors for the creation of new buprenorphine formulations and delivery methods, such as long-acting injectables and implants, which can enhance patient adherence and outcomes. There is also a growing emphasis on integrating OUD treatment into primary care settings, which can destigmatize treatment and make it more accessible. Collaborations between government agencies, healthcare providers, and pharmaceutical companies are fostering comprehensive care models that address the multifaceted needs of individuals with OUD. Moreover, as public awareness about the benefits of medication-assisted treatment (MAT) increases, more patients and healthcare providers are likely to adopt buprenorphine-based therapies. The global push for more sustainable and effective healthcare solutions also aligns with the ongoing efforts to combat the opioid crisis, creating a favorable environment for the growth of the buprenorphine-based OUD treatment market.

BUPRENORPHINE-BASED OPIOID USE DISORDERS (OUD) TREATMENT MARKET REPORT COVERAGE:

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: Drug Delivery Method

• Sublingual

• Subcutaneous

• Film

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Market by Drug Delivery Method, Sublingual market share last year and is poised to maintain its dominance throughout the forecast period. Sublingual buprenorphine has established itself as a leading treatment method for opioid use disorder (OUD) due to its proven efficacy, convenience, and cost-effectiveness. Its effectiveness in reducing cravings and preventing relapse has been well-documented, making it a preferred choice for both patients and healthcare providers. The ease of administration further contributes to its dominance, as patients can use the medication without the need for complex procedures or frequent clinic visits. Widespread availability and physician familiarity with sublingual buprenorphine also support its continued use, and it is generally more affordable compared to other delivery methods. However, the market faces emerging challenges and trends that could impact its leadership. Competition from alternative delivery methods, such as subcutaneous injections and film-based formulations, is growing, offering new options for patients. Ensuring patient adherence remains a challenge, as some individuals may struggle with consistent use of sublingual tablets. Additionally, the presence of counterfeit buprenorphine in the illicit market poses risks to patient safety and treatment outcomes. While sublingual buprenorphine remains the predominant choice for OUD treatment, ongoing monitoring of these challenges and evolving treatment options is crucial to maintaining its position and addressing the dynamic needs of patients.

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: End-User

• Hospitals

• Rehabilitation centers

• Clinics

• Pharmacies

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market by End-Use, Rehabilitation Centers market share last year and is poised to maintain its dominance throughout the forecast period. Rehabilitation centers play a crucial role in the treatment of opioid use disorder (OUD) by providing a comprehensive approach that combines medication-assisted therapy (MAT) with buprenorphine, counseling, and behavioral therapy. These centers offer specialized expertise, with staff trained in addiction treatment to deliver expert care and support. The supportive environment of rehabilitation centers is designed to reduce relapse risks and improve long-term recovery outcomes, emphasizing patient well-being beyond mere medication management. However, several factors could influence their market dominance. Increased access to outpatient care and primary care-based OUD treatment options might shift some demand away from rehabilitation centers. Additionally, the rising costs associated with rehabilitation care could impact patient access and affordability, potentially reducing the appeal of these centers for some individuals. The integration of telehealth services into OUD treatment presents another challenge, as remote consultations and treatments might alter traditional care models and reduce the reliance on in-person rehabilitation centers. Despite these challenges, rehabilitation centers remain pivotal in OUD treatment due to their holistic care approach and specialized support, but adapting to these evolving trends will be essential to maintaining their leading role in the treatment landscape.

Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East and Africa

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market by Region, North America market share last year and is poised to maintain its dominance throughout the forecast period. North America leads the buprenorphine-based opioid use disorder (OUD) treatment market due to the high prevalence of opioid addiction, which has driven substantial demand for effective treatment options. The region has been at the forefront of developing and implementing OUD treatment strategies, including the widespread adoption of buprenorphine. North America benefits from a robust healthcare infrastructure, including specialized treatment facilities and comprehensive healthcare systems, which support the effective delivery of buprenorphine-based therapies. Additionally, increased government funding and supportive initiatives have accelerated market growth, enhancing the availability and accessibility of treatment. However, several challenges could impact North America’s market dominance. Rising treatment costs may limit access for some patients, creating a barrier to widespread adoption. Societal stigma and discrimination associated with addiction treatment continue to pose obstacles, affecting patient willingness to seek help. Moreover, competition from emerging markets, particularly in Asia Pacific, is intensifying as these regions expand their OUD treatment capabilities. To maintain its leadership position, North America must address these challenges by focusing on reducing treatment costs, combating stigma, and adapting to the competitive pressures of rapidly growing global markets.

COVID-19 Impact Analysis on the Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market.

The COVID-19 pandemic has significantly impacted the Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market, creating both challenges and opportunities. During the pandemic, disruptions in healthcare services and lockdown measures led to reduced access to treatment facilities, exacerbating the difficulties for individuals with OUD seeking help. Many patients faced challenges in accessing regular in-person consultations and prescriptions, which heightened the risk of relapse and untreated withdrawal symptoms. However, the crisis also accelerated the adoption of telemedicine, providing a crucial lifeline for OUD patients. Regulatory agencies, such as the DEA in the United States, temporarily relaxed restrictions, allowing for the remote prescription of buprenorphine, which significantly improved treatment continuity. This shift not only mitigated some of the pandemic's negative impacts but also demonstrated the potential for more flexible treatment models. Additionally, the increased focus on mental health and substance use disorders during the pandemic has raised public awareness and government commitment to addressing these issues, resulting in enhanced funding and support for OUD treatment programs. Overall, while the COVID-19 pandemic posed significant challenges, it also catalyzed critical changes in the delivery of buprenorphine-based treatments, paving the way for more accessible and resilient healthcare systems for individuals with OUD.

Latest trends / Developments:

The Global Buprenorphine-based Opioid Use Disorders (OUD) Treatment Market is experiencing several key trends and developments that are shaping its future. One of the most notable trends is the increasing adoption of long-acting buprenorphine formulations, such as extended-release injectables and implants, which offer improved patient adherence and more stable drug levels compared to daily oral tablets. These advancements are helping to enhance treatment efficacy and convenience. Another significant development is the integration of buprenorphine-based treatments into primary care settings, which aims to make treatment more accessible and reduce the stigma associated with addiction treatment. The expansion of telemedicine, accelerated by the COVID-19 pandemic, has also been transformative, allowing for remote consultations and prescriptions that improve access to care, particularly in underserved areas. Additionally, there is a growing emphasis on personalized medicine, with research focusing on tailoring buprenorphine treatment to individual patient needs based on genetic and clinical factors. Increased funding and policy support are driving these innovations, reflecting a broader commitment to addressing the opioid crisis through more effective and accessible treatment options. These trends indicate a dynamic and evolving market, with ongoing advancements aimed at improving patient outcomes and expanding the reach of buprenorphine-based therapies.

Key Players:

1. Indivior PLC

2. Pfizer Inc.

3. Alkermes plc

4. Camurus AB

5. Mylan N.V.

6. Suboxone (Reckitt Benckiser Group)

7. BDSI (BioDelivery Sciences International, Inc.)

8. Nucleus Health

9. Gilead Sciences, Inc.

10. Aquestive Therapeutics, Inc.

11. Johnson & Johnson